Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 16/20 | 0.73 |
| ▸ | MEN1 | O00255 | 10/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | RAD52 | P43351 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829852 | 0.99 | KMT2A (0.72) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2826994 | 0.94 | KMT2A (0.72) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2826989 | 0.92 | MAPK1 (0.77) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2824812 | 0.90 | KMT2A (0.56) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2830103 | 0.88 | TSHR (0.73) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2827744 | 0.87 | TSHR (0.57) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2831270 | 0.87 | TSHR (0.72) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2826587 | 0.87 | TSHR (0.72) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2826515 | 0.86 | TSHR (0.57) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL2826671 | 0.86 | TSHR (0.57) | KMT2AMEN1LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795290-B2 | 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2010-09-14 | — | — | US | claimed |
| EP-2168578-A2 | 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof | Genentech, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. (US) | 2009-02-19 | — | — | US | claimed |
| US-7410988-B2 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2008-08-12 | — | — | US | claimed |
| EP-2620150-A2 | 2-Amido Thiazole Based Inhibitors of ATP-Utilizing Enyzmes | Genentech, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2168578-A2 | 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof | Genentech, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | ATP5ME, ATP5MG, ATP5MK | KMT2A 3547/4885MEN1 2593/4885LMNA 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.